FDA adds heart risk claim to Mounjaro, a first for dual GIP/GLP-1 drugs

The FDA on Aug. 28, 2026 cleared Mounjaro (tirzepatide) for a new use: lowering the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in adults with type 2 diabetes who are at high risk of those events ^[1][3]. It is the first dual GIP and GLP-1 receptor agonist to carry a cardiovascular claim of this kind ^[1][2].

Mounjaro was already sold as a blood sugar treatment, used with diet and exercise in adults and children 10 and older with type 2 diabetes ^[1]. The announcement landed as the European Society of Cardiology opened its annual congress in Munich ^[2].

A comparison against an older GLP-1, not a placebo

The claim rests on SURPASS-CVOT (NCT04255433), a randomized, double-blind phase 3 study that Lilly describes as the first cardiovascular outcomes trial to test two incretin medicines against each other instead of against a placebo ^[1][3]. Researchers enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease at 640 sites in 30 countries, assigning them 1:1 to weekly tirzepatide (15 mg or the highest dose they could tolerate) or weekly dulaglutide (Trulicity) 1.5 mg ^[1][3]. Median follow-up ran 210.1 weeks, and the study lasted about five years ^[1][3].

Tirzepatide met the trial's non-inferiority goal. A first major adverse cardiovascular event occurred in 801 people on tirzepatide (12.2%) and 862 on dulaglutide (13.1%), for a hazard ratio of 0.92 (95.3% CI: 0.83, 1.01) ^[3]. The 8% lower rate favored Mounjaro, but it did not reach statistical significance for superiority (P = .003 for non-inferiority; P = .09 for superiority) ^[3]. Lilly stated that superiority to dulaglutide was not established ^[1]. Full results ran in the New England Journal of Medicine ^[1][3].

David A. D'Alessio, a study co-author and director of the Division of Endocrinology and Metabolism at Duke University School of Medicine, said a large share of type 2 diabetes care focuses on glucose control while cardiovascular risk "can be overlooked" ^[1][2].

Side effects in the trial matched Mounjaro's established profile: mostly gastrointestinal, generally mild to moderate, and concentrated during dose increases ^[1][3]. The label carries a boxed warning about thyroid C-cell tumors and cautions about pancreatitis, low blood sugar when the drug is taken with insulin or sulfonylureas, and dehydration-related kidney injury ^[3].

A separate observational analysis in The BMJ compared people starting tirzepatide with people starting sitagliptin (Januvia) and found lower one-year MACE risk with tirzepatide, 2.9% versus 4.4% (hazard ratio 0.68; number needed to treat 70), while noting that the study design cannot rule out residual confounding ^[3].

Why it matters for patients

Adults with type 2 diabetes and existing heart disease now have another injectable option that regulators say lowers cardiovascular risk. Novo Nordisk's Ozempic is approved to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and Wegovy was approved in March 2024 for adults with heart disease who are overweight or obese ^[2]. Semaglutide, the molecule in both, activates the GLP-1 receptor alone; tirzepatide activates GIP and GLP-1 ^[2].

The wording of the approval matters when weighing options. Because the study was built to show tirzepatide was no worse than dulaglutide, the label does not say Mounjaro prevents heart attacks or strokes better than that older medicine. It says the drug performed at least as well in a population that already had atherosclerotic cardiovascular disease ^[1][3].

Lilly estimates that as many as one in three U.S. adults with type 2 diabetes have cardiovascular disease that has not been detected ^[1]. Whether the new indication shifts insurance coverage or pharmacy benefit rules has not been reported, and no pricing information was disclosed in the announcement ^[1].

What happens next

Data from the trial are already included in Mounjaro's product information in the European Union, and Lilly said regulatory submissions based on SURPASS-CVOT are under review in additional markets ^[1]. The company has not disclosed decision dates for those reviews ^[1].